Avalo Therapeutics (AVTX) Other Gross PP&E Adjustments (2014 - 2026)

Avalo Therapeutics posted quarterly Other Gross PP&E Adjustments of -$268000.0 for Q1 2026, up 56.42% year-on-year from -$171330.6 in Q1 2025, and down 168.0% on a QoQ basis from -$100000.0 in Q4 2025.

Avalo Therapeutics (AVTX) has 13 years of Other Gross PP&E Adjustments data on file, last reported at -$268000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Other Gross PP&E Adjustments rose 56.42% year-over-year to -$268000.0; the trailing twelve-month figure through Mar 2026 stood at -$268000.0 (up 56.42% YoY), and the FY2025 full-year result was -$100000.0, down 113.85% from the prior year.
  • Other Gross PP&E Adjustments for Q1 2026 stood at -$268000.0, down from -$100000.0 in the prior quarter.
  • Across five years, Other Gross PP&E Adjustments topped out at $722000.0 in Q4 2024 and bottomed at -$1.9 million in Q1 2022.
  • The 5-year median for Other Gross PP&E Adjustments is -$1.1 million (2024), against an average of -$802470.6.
  • The widest annual swing landed in 2022, when Other Gross PP&E Adjustments sank 159.74%; it then surged 64.71% in 2025.
  • A 5-year view of Other Gross PP&E Adjustments shows it stood at $582000.0 in 2022, then gained by 23.37% to $718000.0 in 2023, then advanced by 0.56% to $722000.0 in 2024, then slumped by 113.85% to -$100000.0 in 2025, then tumbled by 168.0% to -$268000.0 in 2026.
  • The last three Other Gross PP&E Adjustments figures came in at -$268000.0 (Q1 2026), -$100000.0 (Q4 2025), and -$402000.0 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Other Gross PP&E Adjustments (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -83,048.00
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -60,691.22
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -285.20 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -892,000.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -1.69 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -189.30 Mn
10 Avalo Therapeutics 317.29 Mn 317.29 Mn - -268,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -268,000.00
Mar 31, 2026 -268,000.00
Dec 31, 2025 -100,000.00
Dec 31, 2025 -100,000.00
Sep 30, 2025 -402,000.00
Sep 30, 2025 -402,000.00
Jun 30, 2025 -487,000.00
Jun 30, 2025 -487,000.00
Mar 31, 2025 -615,000.00
Mar 31, 2025 -615,000.00
Dec 31, 2024 722,000.00
Dec 31, 2024 722,000.00
Sep 30, 2024 -1.14 Mn
Sep 30, 2024 -1.14 Mn
Jun 30, 2024 -1.21 Mn
Jun 30, 2024 -1.21 Mn
Mar 31, 2024 -1.28 Mn
Mar 31, 2024 -1.28 Mn
Dec 31, 2023 718,000.00
Dec 31, 2023 718,000.00
Sep 30, 2023 -1.39 Mn
Sep 30, 2023 -1.39 Mn
Jun 30, 2023 -1.46 Mn
Jun 30, 2023 -1.46 Mn
Mar 31, 2023 -1.68 Mn
Mar 31, 2023 -1.68 Mn
Dec 31, 2022 582,000.00
Dec 31, 2022 582,000.00
Sep 30, 2022 -1.81 Mn
Sep 30, 2022 -1.81 Mn
Jun 30, 2022 -1.88 Mn
Jun 30, 2022 -1.88 Mn
Mar 31, 2022 -1.94 Mn
Mar 31, 2022 -1.94 Mn
Dec 31, 2021 587,000.00
Dec 31, 2021 587,000.00
Sep 30, 2021 -698,000.00
Sep 30, 2021 -698,000.00
Jun 30, 2021 -773,000.00
Jun 30, 2021 -773,000.00
Mar 31, 2021 -846,000.00
Mar 31, 2021 -846,000.00
Dec 31, 2020 521,000.00
Dec 31, 2020 521,000.00
Sep 30, 2020 -983,411.00
Sep 30, 2020 -983,411.00
Jun 30, 2020 -1.06 Mn
Jun 30, 2020 -1.06 Mn
Mar 31, 2020 -710,230.00
Mar 31, 2020 -710,230.00
Dec 31, 2019 646,439.00
Dec 31, 2019 646,439.00
Sep 30, 2019 -719,113.00
Sep 30, 2019 -719,113.00
Jun 30, 2019 -728,138.00
Jun 30, 2019 -728,138.00
Mar 31, 2019 -737,658.00
Mar 31, 2019 -737,658.00
Dec 31, 2018 718,675.00
Dec 31, 2018 718,675.00
Dec 31, 2017 -4,457.00
Dec 31, 2017 -4,457.00
Dec 31, 2016 -23,911.00
Dec 31, 2016 -23,911.00
Dec 31, 2015 96,051.00
Dec 31, 2015 96,051.00
Dec 31, 2014 76,068.00
Dec 31, 2014 76,068.00